Wedbush Reiterates "Outperform" Rating for Chimerix (NASDAQ:CMRX)

Wedbush reissued their outperform rating on shares of Chimerix (NASDAQ:CMRX - Free Report) in a report released on Tuesday morning,RTT News reports. The firm currently has a $7.00 target price on the biopharmaceutical company's stock, up from their previous target price of $6.00. Wedbush also issued estimates for Chimerix's Q4 2025 earnings at $0.74 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.58 EPS.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Tuesday.

Chimerix Price Performance

NASDAQ:CMRX traded down $0.01 during midday trading on Tuesday, hitting $5.16. The company's stock had a trading volume of 1,966,316 shares, compared to its average volume of 1,665,403. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53. The firm's 50 day moving average is $3.72 and its 200-day moving average is $1.92. The firm has a market cap of $464.45 million, a P/E ratio of -5.49 and a beta of 0.35.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 20,760 shares of company stock valued at $91,175 in the last 90 days. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bender Robert & Associates purchased a new position in shares of Chimerix during the 4th quarter worth $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix in the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new stake in Chimerix in the 4th quarter valued at about $62,000. Diadema Partners LP purchased a new stake in Chimerix in the 4th quarter valued at about $101,000. Finally, Squarepoint Ops LLC purchased a new stake in Chimerix during the fourth quarter worth about $130,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.